SCHEMBL10162440

SCHEMBL10162440

CC(=O)c1ccc(CNC(=O)c2cc(C(=O)NCc3ccc(F)cc3)nc3ccnn23)cc1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MMP13 P45452 4/20 0.44
ADAMTS4 O75173 1/20 0.44
MMP3 P08254 1/20 0.44
MMP8 P22894 1/20 0.44
MMP12 P39900 1/20 0.44
THRB P10828 1/20 0.43
TP53 P04637 2/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
HTT P42858 1/20 0.41
KCNQ3 O43525 1/20 0.41
KCNQ2 O43526 1/20 0.41
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
TSHR P16473 1/20 0.40
WDR5 P61964 1/20 0.40
ADORA2A P29274 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10162426 0.93 MMP13 (0.53) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10162437 0.92 MMP13 (0.47) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10162483 0.89 POLB (0.47) POLBSMN1; SMN2MMP13THRBTP53
SCHEMBL10162430 0.89 MMP13 (0.45) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10165684 0.87 SMN1; SMN2 (0.48) POLBSMN1; SMN2THRBTP53LMNA
SCHEMBL10162464 0.87 MMP13 (0.53) SMN1; SMN2MMP13ADAMTS4MMP3MMP8
SCHEMBL10162436 0.86 MMP13 (0.46) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10162421 0.85 MMP13 (0.50) POLBSMN1; SMN2MMP13ADAMTS4MMP3
SCHEMBL8258270 0.85 MMP13 (0.61) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10162431 0.84 MMP13 (0.42) MMP13ADAMTS4MMP3MMP8MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 POLB 1285/4885SMN1; SMN2 4594/4885MMP13 1/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 POLB 1285/4885SMN1; SMN2 4594/4885MMP13 1/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 POLB 1285/4885SMN1; SMN2 4594/4885MMP13 1/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 POLB 1285/4885SMN1; SMN2 4594/4885MMP13 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.